DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 204824
» See Plans and Pricing
The generic ingredient in OTREXUP PFS is methotrexate. There are twenty drug master file entries for this compound. Additional details are available on the methotrexate profile page.
Summary for 204824
Tradename: | OTREXUP PFS |
Applicant: | Antares Pharma Inc |
Ingredient: | methotrexate |
Patents: | 12 |
Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 204824
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | 10MG/0.4ML (10MG/0.4ML) | ||||
Approval Date: | Oct 11, 2013 | TE: | RLD: | Yes | |||||
Patent: | Start Trial | Patent Expiration: | Mar 10, 2029 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | Start Trial | Patent Expiration: | Apr 12, 2020 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | Start Trial | Patent Expiration: | Oct 4, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? |
Expired US Patents for NDA 204824
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-002 | Oct 11, 2013 | Start Trial | Start Trial |
Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-002 | Oct 11, 2013 | Start Trial | Start Trial |
Antares Pharma Inc | OTREXUP | methotrexate | SOLUTION;SUBCUTANEOUS | 204824-004 | Oct 11, 2013 | Start Trial | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription